Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Some eye doctors were noticing a trend among patients that researchers in Europe now believe has been well demonstrated with ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

In 2024, new medicines changed how we think about healthy weight loss—but psychological factors remain just as important as ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

On its way out the door, the Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs ...